肥胖危重症患者高蛋白与常规蛋白剂量比较:一项国际实用单盲随机试验的事后分析
该研究为EFFORT Protein试验的事后亚组分析,纳入85个成人ICU、16个国家、BMI≥30 kg/m²的425例肥胖危重症患者,随机接受高剂量蛋白(≥2.2 g/kg/d)或常规剂量蛋白(≤1.2 g/kg/d)。主要终点出院存活时间(TTDA)在高蛋白组无显著获益(HR 0.78,95%CI 0.58-1.05,P=0.10),60天死亡率高蛋白组31.5%对常规组28.2%(风险差3.3%,95%CI -5.4至12.1,P=0.46),机械通气时间和ICU/住院天数无显著差异。结论提示肥胖危重症患者高蛋白剂量未改善临床结局。
要点
- 肥胖(BMI≥30 kg/m²)危重症患者高蛋白剂量(≥2.2 g/kg/d)较常规剂量(≤1.2 g/kg/d)未改善出院存活时间(HR 0.78,95%CI 0.58-1.05,P=0.10)。
- 60天死亡率高蛋白组31.5%对常规组28.2%,风险差3.3%(95%CI -5.4至12.1,P=0.46),无显著差异。
- 高蛋白组机械通气时间、住院时间和ICU停留时间与常规组无显著差异。
- 在不同肥胖分级、营养和衰弱风险亚组中,TTDA均无显著差异,即使排除基线急性肾损伤患者后亦然。
适用人群与场景
- 国际、多中心、实用、注册库为基础的随机试验的事后亚组分析,纳入85个成人ICU、16个国家的肥胖危重症患者,肥胖定义为BMI≥30 kg/m²(n=425)。
诊断标准与关键阈值
- 肥胖定义:BMI≥30 kg/m²。
- 高剂量蛋白组:≥2.2 g/kg/d;常规剂量蛋白组:≤1.2 g/kg/d。
处置流程与药物剂量
- 高剂量蛋白组给予蛋白≥2.2 g/kg/d,常规剂量组给予蛋白≤1.2 g/kg/d,蛋白摄入监测长达28天。
研究设计与关键结果
- 研究类型:EFFORT Protein试验的事后亚组分析,国际、多中心、实用、注册库为基础的随机试验,单盲设计;纳入85个成人ICU、16个国家,BMI≥30 kg/m²的肥胖危重症患者425例(原研究共1301例)。
- 干预:高剂量蛋白(≥2.2 g/kg/d)与常规剂量蛋白(≤1.2 g/kg/d)比较。
- 主要终点:出院存活时间(TTDA),校正中心和协变量后,高蛋白组显示无显著意义的较慢TTDA速率,排除了临床重要获益(HR 0.78,95%CI 0.58-1.05,P=0.10)。
- 亚组分析:不同肥胖分级、有无各种营养和衰弱风险变量的患者中,TTDA均无显著差异,即使排除基线急性肾损伤患者后亦然。
- 60天死亡率:高蛋白组31.5% vs 常规组28.2%,风险差3.3%(95%CI -5.4至12.1,P=0.46)。
- 机械通气时间、住院时间和ICU停留时间:两组无显著差异。
证据类型、等级与局限
- 证据类型:国际、多中心、实用、注册库为基础的随机试验的事后亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在肥胖危重症患者中,高蛋白剂量(≥2.2 g/kg/d)未改善临床结局,包括营养和衰弱风险较高的患者;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Across guidelines, protein dosing for critically ill patients with obesity varies considerably. The objective of this analysis was to evaluate whether this population would benefit from higher doses of protein.
DESIGN: A post hoc subgroup analysis of the effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicenter, pragmatic, registry-based randomized trial.
SETTING: Eighty-five adult ICUs across 16 countries.
PATIENTS: Patients with obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m 2 ( n = 425).
INTERVENTIONS: In the primary study, patients were randomized into a high-dose (≥ 2.2 g/kg/d) or usual-dose protein group (≤ 1.2 g/kg/d).
MEASUREMENTS AND MAIN RESULTS: Protein intake was monitored for up to 28 days, and outcomes (time to discharge alive [TTDA], 60-d mortality, days of mechanical ventilation [MV], hospital, and ICU length of stay [LOS]) were recorded until 60 days post-randomization. Of the 1301 patients in the primary study, 425 had a BMI greater than or equal to 30 kg/m 2 . After adjusting for sites and covariates, we observed a nonsignificant slower rate of TTDA with higher protein that ruled out a clinically important benefit (hazard ratio, 0.78; 95% CI, 0.58-1.05; p = 0.10). We found no evidence of difference in TTDA between protein groups when subgroups with different classes of obesity or patients with and without various nutritional and frailty risk variables were examined, even after the removal of patients with baseline acute kidney injury. Overall, 60-day mortality rates were 31.5% and 28.2% in the high protein and usual protein groups, respectively (risk difference, 3.3%; 95% CI, -5.4 to 12.1; p = 0.46). Duration of MV and LOS in hospital and ICU were not significantly different between groups.
CONCLUSIONS: In critically ill patients with obesity, higher protein doses did not improve clinical outcomes, including those with higher nutritional and frailty risk.
参考来源
- Tweel LE, Compher C, Bear DE, et al. A Comparison of High and Usual Protein Dosing in Critically Ill Patients With Obesity: A Post Hoc Analysis of an International, Pragmatic, Single-Blinded, Randomized Clinical Trial. Crit Care Med. 2023. PMID: 37930244. doi:10.1097/CCM.0000000000006117
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。